Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

Related Citations for PubMed (Select 19307468)

1.

Nanoparticle-mediated drug delivery and pulmonary hypertension.

Bonner JC, Card JW, Zeldin DC.

Hypertension. 2009 May;53(5):751-3. doi: 10.1161/HYPERTENSIONAHA.108.122846. Epub 2009 Mar 23. No abstract available.

2.

Nanoparticle-mediated delivery of nuclear factor kappaB decoy into lungs ameliorates monocrotaline-induced pulmonary arterial hypertension.

Kimura S, Egashira K, Chen L, Nakano K, Iwata E, Miyagawa M, Tsujimoto H, Hara K, Morishita R, Sueishi K, Tominaga R, Sunagawa K.

Hypertension. 2009 May;53(5):877-83. doi: 10.1161/HYPERTENSIONAHA.108.121418. Epub 2009 Mar 23.

3.

Nanoparticle-mediated delivery of pitavastatin into lungs ameliorates the development and induces regression of monocrotaline-induced pulmonary artery hypertension.

Chen L, Nakano K, Kimura S, Matoba T, Iwata E, Miyagawa M, Tsujimoto H, Nagaoka K, Kishimoto J, Sunagawa K, Egashira K.

Hypertension. 2011 Feb;57(2):343-50. doi: 10.1161/HYPERTENSIONAHA.110.157032. Epub 2011 Jan 10.

4.

A nuclear factor-kappaB inhibitor pyrrolidine dithiocarbamate ameliorates pulmonary hypertension in rats.

Sawada H, Mitani Y, Maruyama J, Jiang BH, Ikeyama Y, Dida FA, Yamamoto H, Imanaka-Yoshida K, Shimpo H, Mizoguchi A, Maruyama K, Komada Y.

Chest. 2007 Oct;132(4):1265-74.

PMID:
17934115
5.

Nanoparticle formulations in pulmonary drug delivery.

Bailey MM, Berkland CJ.

Med Res Rev. 2009 Jan;29(1):196-212. doi: 10.1002/med.20140. Review.

PMID:
18958847
6.

Nanoparticle-mediated treatment of pulmonary arterial hypertension.

Mosgoeller W, Prassl R, Zimmer A.

Methods Enzymol. 2012;508:325-54. doi: 10.1016/B978-0-12-391860-4.00017-3. Review.

PMID:
22449934
7.

Toxicological considerations when creating nanoparticle-based drugs and drug delivery systems.

Sharma A, Madhunapantula SV, Robertson GP.

Expert Opin Drug Metab Toxicol. 2012 Jan;8(1):47-69. doi: 10.1517/17425255.2012.637916. Epub 2011 Nov 19. Review.

8.

Simvastatin has beneficial effect on pulmonary artery hypertension by inhibiting NF-κB expression.

Liu ZQ, Liu B, Yu L, Wang XQ, Wang J, Liu HM.

Mol Cell Biochem. 2011 Aug;354(1-2):77-82. doi: 10.1007/s11010-011-0807-4. Epub 2011 Apr 5.

PMID:
21465237
9.

Nanoparticles as drug delivery systems.

Wilczewska AZ, Niemirowicz K, Markiewicz KH, Car H.

Pharmacol Rep. 2012;64(5):1020-37. Review.

10.

Pathophysiological roles of nuclear factor kappaB (NF-kB) in pulmonary arterial hypertension: effects of synthetic selective NF-kB inhibitor IMD-0354.

Hosokawa S, Haraguchi G, Sasaki A, Arai H, Muto S, Itai A, Doi S, Mizutani S, Isobe M.

Cardiovasc Res. 2013 Jul 1;99(1):35-43. doi: 10.1093/cvr/cvt105. Epub 2013 Apr 30.

11.

Targeting CpG oligonucleotides to the lymph node by nanoparticles elicits efficient antitumoral immunity.

Bourquin C, Anz D, Zwiorek K, Lanz AL, Fuchs S, Weigel S, Wurzenberger C, von der Borch P, Golic M, Moder S, Winter G, Coester C, Endres S.

J Immunol. 2008 Sep 1;181(5):2990-8.

12.

Cooperative nanoparticles for tumor detection and photothermally triggered drug delivery.

Park JH, von Maltzahn G, Ong LL, Centrone A, Hatton TA, Ruoslahti E, Bhatia SN, Sailor MJ.

Adv Mater. 2010 Feb 23;22(8):880-5. doi: 10.1002/adma.200902895. No abstract available.

13.

Tissue localization of nanoparticles is altered due to hypoxia resulting in poor efficacy of curcumin nanoparticles in pulmonary hypertension.

Devadasu VR, Wadsworth RM, Ravi Kumar MN.

Eur J Pharm Biopharm. 2012 Apr;80(3):578-84. doi: 10.1016/j.ejpb.2011.12.008. Epub 2011 Dec 30.

PMID:
22227367
14.

Nifedipine nanoparticle agglomeration as a dry powder aerosol formulation strategy.

Plumley C, Gorman EM, El-Gendy N, Bybee CR, Munson EJ, Berkland C.

Int J Pharm. 2009 Mar 18;369(1-2):136-43. doi: 10.1016/j.ijpharm.2008.10.016. Epub 2008 Oct 25.

15.

Hydrophilic multi-walled carbon nanotubes decorated with magnetite nanoparticles as lymphatic targeted drug delivery vehicles.

Yang D, Yang F, Hu J, Long J, Wang C, Fu D, Ni Q.

Chem Commun (Camb). 2009 Aug 7;(29):4447-9. doi: 10.1039/b908012k. Epub 2009 Jun 12.

PMID:
19597621
16.

Local administration of NF-kappa B decoy oligonucleotides to prevent restenosis after balloon angioplasty: an experimental study in New Zealand white rabbits.

Kalinowski M, Viehofer K, Hamann C, Barry JJ, Kleb B, Klose KJ, Wagner HJ, Alfke H.

Cardiovasc Intervent Radiol. 2005 May-Jun;28(3):331-7.

PMID:
15886949
17.

Nuclear factor κB inhibition reduces lung vascular lumen obliteration in severe pulmonary hypertension in rats.

Farkas D, Alhussaini AA, Kraskauskas D, Kraskauskiene V, Cool CD, Nicolls MR, Natarajan R, Farkas L.

Am J Respir Cell Mol Biol. 2014 Sep;51(3):413-25. doi: 10.1165/rcmb.2013-0355OC.

PMID:
24684441
18.

Cell-mediated delivery of nanoparticles: taking advantage of circulatory cells to target nanoparticles.

Anselmo AC, Mitragotri S.

J Control Release. 2014 Sep 28;190:531-41. doi: 10.1016/j.jconrel.2014.03.050. Epub 2014 Apr 18. Review.

PMID:
24747161
19.

A nanoparticle dispersion method for in vitro and in vivo nanotoxicity study.

Kim SC, Chen DR, Qi C, Gelein RM, Finkelstein JN, Elder A, Bentley K, Oberdörster G, Pui DY.

Nanotoxicology. 2010 Mar;4(1):42-51. doi: 10.3109/17435390903374019.

PMID:
20795901
20.

SDF-1α in glycan nanoparticles exhibits full activity and reduces pulmonary hypertension in rats.

Yin T, Bader AR, Hou TK, Maron BA, Kao DD, Qian R, Kohane DS, Handy DE, Loscalzo J, Zhang YY.

Biomacromolecules. 2013 Nov 11;14(11):4009-20. doi: 10.1021/bm401122q. Epub 2013 Oct 18.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk